FDA Plays

[FDA_Player]

you think its a good taktik to buy when it is over with falling?

will it go at 5-7$ ?

how about this:

We continue to be very positive on the Pozen story. The royalty payments off Vimovo and Treximet should drive the company to cash flow positive operations in 2011. The Vimovo approval also validates the pathway for Pozen’s phase III PA-325/40 product, another potential $500+ million idea. Millions of people are taking daily aspirin for cardiovascular secondary prevention, the majority without a gastro-protectant.

PA offers significantly improved GI tolerability to enteric-coated aspirin, and the potential to increase the dose to therapeutic levels that can also treat pain and may reduce the risk of pre-cancerous colon adenomas. We see Pozen fairly-valued at $15 per share